BACKGROUND: Although there is increasing emphasis on introducing palliative care for patients with Heart failure, it is not well characterized where adults with HF spend their final days before death. AIM: This study analyzed the locations and circumstances of death among adults with HF in the United States using data from the CDC-WONDER database. METHODS: The study examined mortality data of individuals aged ≥20 years, with HF listed as the underlying cause of death between 1999 and 2023. The place of death was categorized as the emergency room (ER), hospice/nursing home, inpatient medical facility, or home. Multivariable logistic regression was used to determine the relationship between death location and demographic factors. RESULTS: From 1999 to 2023, HF-related deaths decreased from 1999 (3.60% and 143.6 AAMR) to 2010 (3.47% and 123.1 AAMR). From 2010 onwards, a gradual rise is seen, with the rate of HF deaths reaching 5.18% and 168.1 AAMR in 2023. Notably, deaths at home increased from 18.41% (50,648 of 275,132) in 1999 to 33.47% (132,470 of 395,826) in 2023 and deaths in hospice/nursing homes increased from 30.95% (85,144 of 275,132) in 1999 to 34.71% (116,634 of 336,014) in 2017 and then sudden fall was observed until 2023 to 29.54% (116,931 of 395,826). Older adults (65+) were more likely to die in inpatient facilities. Gender, ethnicity, and urbanization influenced the place of death, with males, whites, and those residing in large metropolitan areas more likely to die in medical facilities. CONCLUSIONS: We highlight the changing patterns in the locations of death among HF patients, emphasizing the need for improved home and hospice care services. Addressing disparities in healthcare access and enhancing palliative care are essential for improving end-of-life experiences. Further research is needed to investigate the factors that contribute to these trends.

The authors have declared no competing interest.

This project did not receive any external funding.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was done using de-identified, publicly available data and is therefore exempt from IRB approval.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data can be provided upon request.